XML 37 R23.htm IDEA: XBRL DOCUMENT
v3.26.1

OTHER OPERATING EXPENSES, NET | 6 Months Ended
--- | ---
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
OTHER OPERATING EXPENSES, NET | OTHER OPERATING EXPENSES, NET Other operating expenses, net for the six months ended June 30, 2026 and 2025 are summarized below (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2026 |  | 2025 |  | 2026 |  | 2025
Divestiture-related expenses | $ | 5,931 |  |  | $ | — |  |  | $ | 5,931 |  |  | $ | — |
Contingent consideration charges (gains) | 1,663 |  |  | (357) |  |  | (614) |  |  | (3,032) |
Acquisition-related expenses | — |  |  | 991 |  |  | — |  |  | 2,502 |
Legal settlement | — |  |  | — |  |  | — |  |  | 7,000 |
Total other operating expenses, net | $ | 7,594 |  |  | $ | 634 |  |  | $ | 5,317 |  |  | $ | 6,470 |
Divestiture-Related Expenses The Company recognized divestiture-related expenses of $5.9 million during the three and six months ended June 30, 2026, primarily related to third-party services and legal fees associated with divesting iovera° to Zimmer. For more information, see Note 3, Assets and Liabilities Held for Sale. Flexion Acquisition Contingent Consideration The Company recognized contingent consideration charges of $1.7 million and gains of $0.6 million during the three and six months ended June 30, 2026, respectively. The Company recognized contingent consideration gains of $0.4 million and $3.0 million during the three and six months ended June 30, 2025, respectively. See Note 11, Financial Instruments, for information regarding the method and key assumptions used in the fair value measurements of contingent consideration and more information regarding the changes in fair value. Acquisition-Related Expenses The Company recognized acquisition-related expenses of $1.0 million and $2.5 million during the three and six months ended June 30, 2025, respectively, primarily related to third-party services and legal fees associated with the GQ Bio Acquisition. Legal Settlement The Company recognized $7.0 million of costs during the six months ended June 30, 2025 related to the patent infringement suits against the eVenus ANDA Filers (as defined below). For more information, see Note 17, Commitments and Contingencies.

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other operating income and other operating expense items. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details
Name: | us-gaap_OtherOperatingIncomeAndExpenseTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration